Therapeutics

#Biopharmaceuticals #Drug discovery #Drug targets #Drug technology #Pharmaceuticals #Quantum computing #R&D #Therapeutics

Podcast: Complex problems require complex solutions

This is the latest episode of the free DDW podcast, “Complex problems require complex solutions”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How quantum computing can benefit drug discovery” and “Sitting down with Dr Michael Hayden from… Read More

#News

#Biologics #Biotechnology #Funding #Seed funding #Therapeutics

How will $41 million be used to fight chronic and age-related diseases? 

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics… Read More

#Business & Investment #News

#Biotechnology #Collaboration #Drug targets #Therapeutics

Collaboration to stabilise a challenging drug target  

Swedish biotech company Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target.  The collaboration brings together Salipro Biotech’s services in developing stable antigens of GPCRs, ion channels and transporters via its proprietary… Read More

#News

#Avacta #Clinical diagnostics #Therapeutics

New vodcast on Avacta’s Open Day 2022

Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters at Scale Space in Imperial College’s White City Campus, London. DDW Multimedia Editor Megan Thomas attended the open day to learn more about the company’s intentions. In this video, she speaks… Read More

#News

MHRA
#AAV #Geographic atrophy #MHRA #Therapeutics

Green light for potential AAV gene therapy 

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with… Read More

#News #Regulatory

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer. Amid continued… Read More

#News

#Collaboration #Cystic fibrosis #Neuropsychiatric disorders #RNA #Therapeutics

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available for download. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This round-up was compiled by DDW’s Diana Spencer and reflects… Read More

#News

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

#Cell therapy #Flow Cytometry #Immunogenicity #Podcast #Technology #Therapeutics

New podcast: Revealing the magic of cell therapy

This is the latest episode of the free DDW podcast, “Revealing the magic of cell therapy”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “The magic of cell therapy” and “Cellular assays to bridge the gap… Read More

#News

#Antibodies #Antibody reagents #Assays #Therapeutics

Generating and validating critical antibody reagents: event

Antibodies are critical reagents applied in multiple biological areas, such as scientific research, therapeutics, and diagnosis. High-quality and reliable antibody reagents are the foundation of good assay performance. To learn more generating and validating critical antibody reagents join this free event hosted by DDW and supported by Sino Biological. It… Read More

#News

#Clinical trial #Drug development #Drug discovery #Therapeutics

Rani Therapeutics initiates Phase I study osteoporosis drug 

Rani Therapeutics, a clinical stage biotherapeutics company focused on the oral delivery of biologics, has initiated a Phase I study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via capsule.  The first subject has been administered RT-102… Read More

#News

#Cancer #Lung cancer #Therapeutics

Partnership identifies novel small molecule inhibitors for lung cancer  

Arctoris and Evariste Technologies have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients with Non-Small Cell Lung Cancer (NSCLC).   Current treatment options  Current treatment options for NSCLC are limited, especially in advanced stages. It has been shown that… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug discovery #Pharmaceutical #Therapeutics #Women in STEM

International Women’s Day: Female achievement in drug discovery

The theme for International Women’s Day 2022 is ‘Break the Bias’, in which society is encouraged to celebrate women's achievements, in turn raising awareness against bias and inspiring positive action for equality. Though the initiative is interdisciplinary, the drug discovery, life science and pharmaceutical world boasts many achievements of this… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trending News

Sickle cells
#GlobalData #Sickle cells #Therapeutics

How US sickle cell disease market will reach $4.8 billion by 2030 

A number of new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure.   The cause of the increase  GlobalData notes that one of the gene therapies that is currently closest to… Read More

#News

#Antigen #Biotechnology #Immunology / Virology & Vaccines #mRNA #RNA #Therapeutics

What’s next for RNA-based medicine post-Covid-19?

Dr Pirkko Muhonen, Senior Field Application Scientist, Nucleic Acid Therapeutics, at Thermo Fisher Scientific, shares what's next for RNA-based medicine post-pandemic with DDW. With SARS-CoV-2 circulating the globe and leading to over five million deaths worldwide1, all eyes are on the critical role messenger RNA (mRNA) vaccines are playing in… Read More

#Covid-19 #Exclusive Content #News #Trends & Analysis

Human liver
#Clinical trials #Liver disease #Oncology #Therapeutics #Tumours

First patient dosed in advanced liver cancer clinical trial 

MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).  What is OUTREACH-2?  OUTREACH-2 is a multi-centre,… Read More

#News #Trending News